---
figid: PMC8269276__JEP-13-627-g0001
figtitle: 'Promising Treatment Options for Axial Spondyloarthritis: An Overview of
  Experimental Pharmacological Agents'
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC8269276
filename: JEP-13-627-g0001.jpg
figlink: /pmc/articles/PMC8269276/figure/f0001/
number: F1
caption: '(A) The JAK-Stat signalling pathway. (B) Cytokine signally through JAK/STAT
  combination. Adapted from Bechman K, Yates M, Golloway J. The new entries in the
  therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacol Res. 2020;
  153: 104634. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
  Adapted from Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling
  through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285
  (1–2):1–24. Feb 20. Copyright 2002, with permission from Elsevier. Adapted from
  Hodge AJ, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib
  – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin
  Exp Rheumatol. 2016; 34 (2):318-328.'
papertitle: 'Promising Treatment Options for Axial Spondyloarthritis: An Overview
  of Experimental Pharmacological Agents.'
reftext: Hasan Tahir, et al. J Exp Pharmacol. 2021;13:627-635.
year: '2021'
doi: 10.2147/JEP.S262340
journal_title: Journal of Experimental Pharmacology
journal_nlm_ta: J Exp Pharmacol
publisher_name: Dove
keywords: Axial spondyloarthritis | novel therapies | JAK inhibitors | IL-17 inhibitors
  | GM-CSF inhibitors
automl_pathway: 0.9533638
figid_alias: PMC8269276__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC8269276__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8269276__JEP-13-627-g0001.html
  '@type': Dataset
  description: '(A) The JAK-Stat signalling pathway. (B) Cytokine signally through
    JAK/STAT combination. Adapted from Bechman K, Yates M, Golloway J. The new entries
    in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacol
    Res. 2020; 153: 104634. This is an open access article under the CC BY license
    (http://creativecommons.org/licenses/by/4.0/). Adapted from Kisseleva T, Bhattacharya
    S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent
    advances and future challenges. Gene. 2002;285 (1–2):1–24. Feb 20. Copyright 2002,
    with permission from Elsevier. Adapted from Hodge AJ, Kawabata TT, Krishnaswami
    S, et al. The mechanism of action of tofacitinib – an oral Janus kinase inhibitor
    for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016; 34 (2):318-328.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Il2
  - Il9
  - Il4
  - Il7
  - Il15
  - Il21
  - Jak3
  - Jak1
  - Stat6
  - Stat5a
  - Stat3
  - Stat1
  - Jak2
  - Ifng
  - Ifna
  - Ifnb1
  - Il22
  - Il10
  - Tyk2
  - Gast
  - Gnas
  - Il23a
  - Stat4
  - Csf2
  - Tpo
  - Thpo
  - Epo
  - Epx
  - Il6
  - IL2
  - IL9
  - IL4
  - IL7
  - LINC02605
  - IL15
  - IL22
  - IL21
  - JAK3
  - JAK1
  - STAT6
  - STAT5A
  - STAT5B
  - STAT3
  - STAT1
  - SOAT1
  - STAT2
  - STAT4
  - JAK2
  - TYK2
  - IFNG
  - IFN1@
  - IFNA1
  - IFNA2
  - IFNA17
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA21
  - IFNB1
  - IL10
  - GAST
  - GALNS
  - PAGR1
  - IL37
  - IL23A
  - IL12A
  - IL12B
  - CSF2
  - TPO
  - THPO
  - EPO
  - TIMP1
  - EPX
  - IL6
---
